Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADXS
Previous Symbol
CUSIPN/A
Phone609-452-9813
Debt
Debt-to-Equity RatioN/A
Current Ratio3.95
Quick Ratio3.95
Price-To-Earnings
Trailing P/E Ratio-0.22
Forward P/E Ratio-0.46
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.03 million
Price / Sales2.18
Cash FlowN/A
Price / CashN/A
Book Value$1.32 per share
Price / Book0.38
Profitability
EPS (Most Recent Fiscal Year)($2.31)
Net Income$-93,430,000.00
Net Margins-1,062.68%
Return on Equity-165.23%
Return on Assets-91.46%
Miscellaneous
Employees108
Outstanding Shares52,830,000
Market Cap$25.62 million
OptionableOptionable
Advaxis (NASDAQ:ADXS) Frequently Asked Questions
What is Advaxis' stock symbol?
Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How were Advaxis' earnings last quarter?
Advaxis, Inc. (NASDAQ:ADXS) released its quarterly earnings results on Monday, September, 10th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.02. The biotechnology company earned $1.13 million during the quarter, compared to the consensus estimate of $1.85 million. Advaxis had a negative net margin of 1,062.68% and a negative return on equity of 165.23%. View Advaxis' Earnings History.
When is Advaxis' next earnings date?
What price target have analysts set for ADXS?
3 equities research analysts have issued 12 month price targets for Advaxis' stock. Their forecasts range from $2.00 to $5.00. On average, they expect Advaxis' stock price to reach $3.00 in the next year. This suggests a possible upside of 503.9% from the stock's current price. View Analyst Price Targets for Advaxis.
What is the consensus analysts' recommendation for Advaxis?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Advaxis.
Has Advaxis been receiving favorable news coverage?
News coverage about ADXS stock has trended positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Advaxis earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Advaxis' key competitors?
Some companies that are related to Advaxis include Tetraphase Pharmaceuticals (TTPH), Northwest Biotherapeutics (NWBO), Aridis Pharmaceuticals (ARDS), Vernalis (VNLPY), Chembio Diagnostics (CEMI), Provention Bio (PRVB), Chiasma (CHMA), CTI BioPharma (CTIC), Scpharmaceuticals (SCPH), Zynerba Pharmaceuticals (ZYNE), Synergy Pharmaceuticals (SGYP), PhaseBio Pharmaceuticals (PHAS), Evofem Biosciences (EVFM), BELLUS Health (BLUSF) and Axsome Therapeutics (AXSM).
Who are Advaxis' key executives?
Advaxis' management team includes the folowing people:
- Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 58)
- Mr. Anthony A. Lombardo, Exec. Officer (Age 69)
- Mr. Kenneth A. Berlin, Pres, CEO and Director (Age 54)
- Ms. Molly Henderson CPA, MBA, Exec. VP & CFO (Age 47)
- Mr. Mayo Pujols, Sr. VP of Technical Operations
Who are Advaxis' major shareholders?
Advaxis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.26%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Robert Petit, Roni Appel, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.
Which major investors are buying Advaxis stock?
How do I buy shares of Advaxis?
Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Advaxis' stock price today?
One share of ADXS stock can currently be purchased for approximately $0.4968.
How big of a company is Advaxis?
Advaxis has a market capitalization of $25.62 million and generates $12.03 million in revenue each year. The biotechnology company earns $-93,430,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Advaxis employs 108 workers across the globe.
What is Advaxis' official website?
How can I contact Advaxis?
Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]
MarketBeat Community Rating for Advaxis (NASDAQ ADXS)
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
